Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blinded study in Sweden evaluating the efficacy of 3 dosage regimens of PIVYA tablets

Next Previous
X
Search
Trial Profile

A multi-center, randomized, double-blinded study in Sweden evaluating the efficacy of 3 dosage regimens of PIVYA tablets

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pivmecillinam (Primary) ; Cefalexin
  • Indications Urinary tract infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 May 2024 New trial record
    • 24 Apr 2024 According to U.S. Food and Drug Administration media release, US Food and Drug Administration (FDA) approved the oral antibiotic pivmecillinam for treating uncomplicated urinary tract infections (uUTIs). The FDA said approval was based on results from three randomized controlled trials that compared pivmecillinam to placebo, to another antibiotic, and to an anti-inflammatory.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top